Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2839 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Sygnature Discovery–BioStrata: public relations, 201902 service existent by BioStrata 2019-02-15
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Consilium: public relations, 201902 service existent by CSC 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Pathios Therapeutics–Sygnature Discovery: drug discovery services, 201902– collab service discovery for GPCR target in autoimmune diseases + cancer 2019-02-07
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinals diases 2019-01-31
Horizon Discovery–Rutgers Univ: gene editing technology, 201901– collab strategic developm + excl license option for base editing technology 2019-01-28
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital 2019-01-22
Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals 2019-01-22
ATUM–Solentim: cell line development technology, 201901– collab product integration of VIPS hardware + Leap-In Transposase expression technology 2019-01-14
Solentim–Sciad Communications: public relations, 201901 service existent by Sciad 2019-01-14
Chronomics–SEVERAL: investment, 201901 seed financing round £1.12m from Anthemis + SOSV 2019-01-10
Orchard Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Orchard presents at JP Morgan Healthcare Conference 2019 2019-01-09
AstraZeneca–Aptamer Group: aptamer drug conjugates, 201901– collab research to enable drug delivery to the kidney 2019-01-07
Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp 2019-01-07
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum 2019-01-07
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Confo Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif for international media 2019-01-03
Fujifilm–Zyme Communications: public relations, 201901 service existent for Fujifilm Irvine Scientific by Zyme 2019-01-02
Procarta Biosystems–Novo Group: investment, 2018 investment €1.5m by Novo REPAIR Impact Fund 2018-12-31
Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS 2018-12-24
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation 2018-12-24
Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management 2018-12-24
Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health 2018-12-24
Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital 2018-12-24
Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech 2018-12-24
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Morphogen-IX–Cambridge Innovation Capital: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor CIC 2018-12-20
Morphogen-IX–Medicxi Ventures: investment, 201812 financing round Series B totalling £18.4m incl existing + lead investor Medicxi 2018-12-20
Morphogen-IX–SEVERAL: investment, 201812 financing round Series B £18.4m ($23.2m) led by Medicxi + incl CIC + Cambridge Enterprise 2018-12-20
Morphogen-IX–Univ Cambridge: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor Cambridge Enterprise 2018-12-20
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Synthace–SEVERAL: investment, 201812 financing round Series B $25.6m led by Horizons Ventures 2018-12-12
AstraZeneca–Cancer Research UK: functional genomics, 201812– collab establishment of joint venture Functional Genomics Centre in Cambridge 2018-12-10
Genomics plc–F-Prime: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
Genomics plc–Foresite Capital: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
Genomics plc–SEVERAL: investment, 201812 financing round Series B 2nd closing £8m from Foresite Capital + F-Prime Capital bringing total round to £33m 2018-12-10
Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare 2018-12-10
Tesaro–GSK: investment, 201812–201901 acquisition $5.1b (£4b) in cash incl net debt assumption of Tesaro Inc by GSK 2018-12-03
Igem Therapeutics–SEVERAL: investment, 201811 financing round Series £3m final closing bringing total round to £5m 2018-11-30
Autolus–AbCellera: drug target discovery, 201811– collab discovery of antibodies for targeted CAR-T cell therapies 2018-11-29
F2G Ltd–Evercore: investor conference, 201811 supply service F2G presents at Evercore ISI HealthCONx Conference 2018 2018-11-28
ABP (NL)–Optimum Strategic Communications: public relations, 201811 service existent by Optimum for Inkef Capital 2018-11-27
Allogene Therapeutics–Piper Jaffray: investor conference, 201811 supply service Allogene presents at Piper Jaffray Healthcare Conference in NYC 2018-11-27
Engitix–Instinctif Partners: public relations, 201811 service existent by Instinctif 2018-11-27
Engitix–SEVERAL: investment, 201811 financing round Series A £5m led by private investor 2018-11-27
Genomics Medicine Ireland–Wuxi PharmaTech: investment, 201811 acquisition of Ireland Medicine Ireland by WuXi NextCode 2018-11-27
Nabriva–Piper Jaffray: investor conference, 201811 supply service Nabriva presents at Piper Jaffray Healthcare Conference in NYC 2018-11-27
Fluidic Analytics–Amadeus Capital: investment, 201811 financing round totalling $31m incl existing + co-investor Amadeus Capital Partners 2018-11-26
Fluidic Analytics–BGF: investment, 201811 financing round totalling $31m incl new + co-investor BGF 2018-11-26
Fluidic Analytics–Delin Ventures: investment, 201811 financing round totalling $31m incl new + co-investor Delin Ventures 2018-11-26
Fluidic Analytics–Draper Esprit: investment, 201811 financing round totalling $31m incl existing + lead investor Draper Esprit 2018-11-26
Fluidic Analytics–IQ Capital: investment, 201811 financing round totalling $31m incl existing + co-investor IQ Capital 2018-11-26
Fluidic Analytics–SEVERAL: investment, 201811 financing round $31m led by existing investor Draper Esprit 2018-11-26
Immune Regulation–Instinctif Partners: public relations, 201811 service existent by Instinctif 2018-11-26
SeraCare–LGC: investment, 201811 acquisition of SeraCare owned by Linden Capital Partners by LGC owned by KKR 2018-11-26
Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE 2018-11-26
Oxford BioMedica–United Kingdom (govt): grant, 201811 Innovate UK grant £2m to support digitallisation of gene/cell therapy production 2018-11-23
F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d 2018-11-22
Kyowa Hakko Kirin–GSK: daprodustat, 201811– collab €na commercialisation of daprodustat in Japan by Kyowa Hakko Kirin 2018-11-22
OMass–SEVERAL: investment, 201811 financing round Series A £14m led by new investor Syncona Ltd plus Oxford Sciences Innovation 2018-11-21
OMass–Univ Oxford: investment, 201811 financing round Series A totalling £14m incl existing + co-investor Oxford Sciences Innovation 2018-11-21
OMass–Wellcome Trust: investment, 201811 financing round Series A totalling £14m incl new + lead investor Syncona Ltd 2018-11-21
Denali Therapeutics–WPP: public relations, 201811 service existent by Glover Park Group 2018-11-19
Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners 2018-11-19
Inflazome–Fountain Healthcare Partners: investment, 201811 financing round Series B totalling €40m incl existing + co-investor FHP 2018-11-19
Inflazome–Longitude Capital: investment, 201811 financing round Series B totalling €40m incl new + co-investor Longitude Capital 2018-11-19
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners 2018-11-19
Roche–Immunocore: ImmTAC technology, 201811– collab expansion co-developm of IMC-C103C with $100m upfront/near-term with Genentech 2018-11-19
Aimmune Therapeutics–Leucadia: investor conference, 201811 supply service Aimmune attends Jefferies 2018 London Healthcare Conference 2018-11-15
Helomics–United Kindgom (govt): personalised medicine, 201811– collab access to 100k Genomces Project data for precision medicine for ovarian cancer 2018-11-15
Allogene Therapeutics–Leucadia: investor conference, 201811 supply service Allogene presents at Jefferies 2018 London Healthcare Conference 2018-11-14
Erytech–Leucadia: investor conference, 201811 supply service Erytech at Jefferies London Healthcare Conference 2018 2018-11-14
Oryzon Genomics–Leucadia: investor conference, 201811 supply service Oryzon attends Jefferies London Healthcare Conference 2018 2018-11-14
Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic 2018-11-14
Hox Therapeutics–Optimum Strategic Communications: public relations, 201811 service existent by Optimum 2018-11-13
Amal Therapeutics–SEVERAL: investment, 201811 financing round Series B 2nd + final closing €21.2m co-led by BIVF + BioMedPartners + Helsinn 2018-11-12
Harpoon Therapeutics–SEVERAL: investment, 201811 financing round Series C $70m led by OrbiMed 2018-11-11
Edinburgh Molecular Imaging–Optimum Strategic Communications: public relations, 201811 service existent by Optimum 2018-11-08
Sitryx Therapeutics–Sygnature Discovery: drug discovery services, 201811– collab service multi-target drug discovery in I-O + immuno-inflammation 2018-11-08
Orchard Therapeutics–SEVERAL: investment, 201811 IPO $225.5m with 16.1m ADSs at $14/ADS at Nasdaq Global Select Market 2018-11-05
Cristal Therapeutics–Instinctif Partners: public relations, 201811 service existent by Instinctif 2018-11-02
DefiniGen–MIT: CRISPR technology, 201810– commercial license to CRISPR-Cas9 gene editing technology from Broad Institute 2018-10-30
Grünenthal–AstraZeneca: esomeprazole, 201810– acquisition $922m of European rights to Nexium + ww ex US+JP rights to Vimovo 2018-10-30
Euformatics–EU (govt): grant, 201810– H2020 grant €700k for participation in GEMMA project 2018-10-25
Microbiotica–BPCE: investment, 201810 investment £4m by Seventure Partners’ Health for Life Capital Fund 2018-10-24
Microbiotica–Wellcome Trust: investment, 20810 exising investor Wellcome Sanger Institute 2018-10-24
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px

» top